Yu-Shan Hsieh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yu-Shan Hsieh has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Geun Hee Seol
Department of Basic Nursing Science, College of Nursing, Korea University, Seoul 02841, Republic of Korea
7 shared publications Soonho Kwon
Department of Basic Nursing Science, School of Nursing, Korea University, Seoul 02841, Republic of Korea
6 shared publicationsYou Kyoung Shin
Department of Basic Nursing Science, School of Nursing, Korea University, Seoul 02841, Republic of Korea
6 shared publicationsShuen-Fu Weng
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Medical University Hospital, Taipei City, 11031, Republic of China, Taiwan
4 shared publicationsYu-Pei Lin
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Medical University Hospital, Taipei City, Taiwan
4 shared publications- A. Young Han
Department of Nursing, College of Life Science and Industry, Sunchon National University, 255, Jungang-ro, Suncheon-Si, Jeollanam-do 57922, Republic of Korea
3 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-8
Association Between Low-Dose Aspirin Use and Early Renal Injury Biomarkers in Patients with Type 2 Diabetes Mellitus: A Retrospective Matched Cohort Study
Purpose: Microalbuminuria and urine albumin-to-creatinine ratio (UACR) are important markers for early diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM). Aspirin (acetylsalicylic acid; ASP) has been associated with anti-inflammatory and metabolic effects in patients with T2DM. This study investigated the association between low-dose ASP use and renal injury markers in patients with T2DM. Methods: A retrospective matched cohort study was conducted in 60 Taiwanese patients with T2DM. Patients receiving low-dose ASP (100 mg/day) were matched 1:1 with controls according to sex, age, height, weight, body mass index, and duration of diabetes. Metabolic outcomes and renal injury markers, including serum creatinine, urine microalbumin, and urine albumin-to-creatinine ratio (UACR), were evaluated during follow-up. Results: Compared with the DM group, the ASP group demonstrated lower HbA1c and total cholesterol levels during follow-up. In renal outcome analysis, urine microalbumin levels were significantly lower in the ASP group than in the DM group at follow-up (p = 0.039). A trend toward improved UACR was also observed in the ASP group. Conclusion: Low-dose ASP use was associated with favorable changes in glycemic control and early renal injury markers in patients with T2DM. Lower urine microalbumin levels and a trend toward improved UACR were observed in the ASP group during follow-up. Although microalbuminuria may be influenced by multiple metabolic and cardiovascular factors, the present findings suggest that low-dose ASP therapy may have potential metabolic and renal associations in patients with T2DM. Further prospective studies are warranted to validate these findings and to explore the underlying mechanisms and their clinical relevance.
- 1 July 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-8
Open AccessAssociation Between Low-Dose Aspirin Use and Early Renal Injury Biomarkers in Patients with Type 2 Diabetes Mellitus: A Retrospective Matched Cohort Study
Purpose: Microalbuminuria and urine albumin-to-creatinine ratio (UACR) are important markers for early diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM). Aspirin (acetylsalicylic acid; ASP) has been associated with anti-inflammatory and metabolic effects in patients with T2DM. This study investigated the association between low-dose ASP use and renal injury markers in patients with T2DM. Methods: A retrospective matched cohort study was conducted in 60 Taiwanese patients with T2DM. Patients receiving low-dose ASP (100 mg/day) were matched 1:1 with controls according to sex, age, height, weight, body mass index, and duration of diabetes. Metabolic outcomes and renal injury markers, including serum creatinine, urine microalbumin, and urine albumin-to-creatinine ratio (UACR), were evaluated during follow-up. Results: Compared with the DM group, the ASP group demonstrated lower HbA1c and total cholesterol levels during follow-up. In renal outcome analysis, urine microalbumin levels were significantly lower in the ASP group than in the DM group at follow-up (p = 0.039). A trend toward improved UACR was also observed in the ASP group. Conclusion: Low-dose ASP use was associated with favorable changes in glycemic control and early renal injury markers in patients with T2DM. Lower urine microalbumin levels and a trend toward improved UACR were observed in the ASP group during follow-up. Although microalbuminuria may be influenced by multiple metabolic and cardiovascular factors, the present findings suggest that low-dose ASP therapy may have potential metabolic and renal associations in patients with T2DM. Further prospective studies are warranted to validate these findings and to explore the underlying mechanisms and their clinical relevance.
- Open Access
- 22 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0351553
Effects of incentive spirometer training on dyspnea and functional status in patients with long COVID
Background: Since the emergence of Coronavirus Disease 2019 (COVID-19), it has become a global pandemic, profoundly affecting public health and daily life. Many recovering individuals report persistent or recurrent symptoms—fatigue, palpitations, cognitive impairment, shortness of breath, anxiety, and chest discomfort. These lingering effects impair work, daily function, and social interaction, placing a significant burden on individual quality of life and society. Objective: This study aims to evaluate the effectiveness of using an induced Incentive Spirometer as a respiratory training tool to relieve long COVID symptoms. Methods: This study, conducted from July 1, 2023, to May 11, 2024, at a regional teaching hospital in northern Taiwan, involved participants who had recovered from COVID-19 within the past year and had at least one long COVID respiratory symptom. Participants were assigned to one waiting control group and four experimental groups based on recovery time: within 3 months (Experimental Group 1), 3–6 months (Experimental Group 2), 6–9 months (Experimental Group 3), and 9–12 months (Experimental Group 4). The waiting control group received no interventions, while the experimental groups underwent inspiratory training using an induced Incentive Spirometer three times a week for 6 weeks (30 repetitions per session). Assessments were conducted before and after the intervention. Primary outcomes were the Dyspnoea-12 scale and Post-COVID-19 Functional Status scale. Secondary outcomes included the 6-minute walk distance and CaO₂. Results: Ninety participants were enrolled, with five withdrawing, leaving 85 for final analysis. After 6 weeks of intervention, the waiting control group showed no significant changes in dyspnea ( p = 0.463) or post-COVID-19 functional status ( p = 0.343). In contrast, all experimental groups showed significant improvements. Dyspnoea-12 scale scores improved in Experimental Groups 1 ( p < 0.001), 2 ( p = 0.008), 3 ( p = 0.011), and 4 ( p = 0.001). The Post-COVID-19 Functional Status scale also showed improvements in all Experimental Groups (Group 1: p < 0.001, Group 2: p = 0.003, Group 3: p = 0.002, and Group 4: p = 0.011). Significant improvements in 6-min walk distance were observed in some experimental groups, improvements were seen in Experimental Groups 1 ( p < 0.001), 2 ( p = 0.027), 3 ( p = 0.68), and 4 ( p = 0.172). No significant changes in CaO2 were observed (pre-test, p = 0.872 and post-test, p = 0.585). Conclusion: Respiratory training using an induced Incentive Spirometer may help alleviate dyspnea and improve post-COVID-19 functional status in individuals with Long COVID. Earlier intervention appeared to yield better outcomes, although improvements were also observed even 9–12 months after infection. However, further studies with comprehensive pulmonary assessments are needed to confirm these findings. Clinical trial number: NCT06165835, registered on 9 December 2023.
- 22 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0351553
Open AccessEffects of incentive spirometer training on dyspnea and functional status in patients with long COVID
Background: Since the emergence of Coronavirus Disease 2019 (COVID-19), it has become a global pandemic, profoundly affecting public health and daily life. Many recovering individuals report persistent or recurrent symptoms—fatigue, palpitations, cognitive impairment, shortness of breath, anxiety, and chest discomfort. These lingering effects impair work, daily function, and social interaction, placing a significant burden on individual quality of life and society. Objective: This study aims to evaluate the effectiveness of using an induced Incentive Spirometer as a respiratory training tool to relieve long COVID symptoms. Methods: This study, conducted from July 1, 2023, to May 11, 2024, at a regional teaching hospital in northern Taiwan, involved participants who had recovered from COVID-19 within the past year and had at least one long COVID respiratory symptom. Participants were assigned to one waiting control group and four experimental groups based on recovery time: within 3 months (Experimental Group 1), 3–6 months (Experimental Group 2), 6–9 months (Experimental Group 3), and 9–12 months (Experimental Group 4). The waiting control group received no interventions, while the experimental groups underwent inspiratory training using an induced Incentive Spirometer three times a week for 6 weeks (30 repetitions per session). Assessments were conducted before and after the intervention. Primary outcomes were the Dyspnoea-12 scale and Post-COVID-19 Functional Status scale. Secondary outcomes included the 6-minute walk distance and CaO₂. Results: Ninety participants were enrolled, with five withdrawing, leaving 85 for final analysis. After 6 weeks of intervention, the waiting control group showed no significant changes in dyspnea ( p = 0.463) or post-COVID-19 functional status ( p = 0.343). In contrast, all experimental groups showed significant improvements. Dyspnoea-12 scale scores improved in Experimental Groups 1 ( p < 0.001), 2 ( p = 0.008), 3 ( p = 0.011), and 4 ( p = 0.001). The Post-COVID-19 Functional Status scale also showed improvements in all Experimental Groups (Group 1: p < 0.001, Group 2: p = 0.003, Group 3: p = 0.002, and Group 4: p = 0.011). Significant improvements in 6-min walk distance were observed in some experimental groups, improvements were seen in Experimental Groups 1 ( p < 0.001), 2 ( p = 0.027), 3 ( p = 0.68), and 4 ( p = 0.172). No significant changes in CaO2 were observed (pre-test, p = 0.872 and post-test, p = 0.585). Conclusion: Respiratory training using an induced Incentive Spirometer may help alleviate dyspnea and improve post-COVID-19 functional status in individuals with Long COVID. Earlier intervention appeared to yield better outcomes, although improvements were also observed even 9–12 months after infection. However, further studies with comprehensive pulmonary assessments are needed to confirm these findings. Clinical trial number: NCT06165835, registered on 9 December 2023.
- Open Access
- 9 June 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (12) , 1630
Association Between Prior NRICM101 Use and Response to Incentive Spirometer Training in Patients with Long COVID
Background: Inspiratory training using an incentive spirometer (IS) improves respiratory symptoms and functional status in Long COVID. In Taiwan, NRICM101 is commonly used during the acute phase; however, its impact on rehabilitation outcomes remains unclear. Objective: This study evaluated the effects of IS-based respiratory training and the potential influence of prior NRICM101 use. Methods: Participants were grouped by time since recovery, and pre-post changes after six weeks of IS training were compared between those with and without self-reported prior NRICM101 use. Primary outcomes were dyspnea and functional status; secondary outcomes included six-minute walk distance and arterial oxygen content. Results: IS training significantly improved dyspnea (p < 0.0001), functional status (p < 0.0001), and exercise endurance (NRICM101 group: p = 0.002; no NRICM101 group: p < 0.0001). Stratified analysis showed that when initiated within three months of recovery, participants without prior NRICM101 use had greater improvements in dyspnea (p < 0.0001), functional status (p = 0.001), and exercise endurance (p < 0.0001). Conclusions: Prior NRICM101 use may be associated with different rehabilitation patterns, likely reflecting differences in recovery trajectory or patient behavior rather than purely pharmacological effects.
- 9 June 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (12) , 1630
Open AccessAssociation Between Prior NRICM101 Use and Response to Incentive Spirometer Training in Patients with Long COVID
Background: Inspiratory training using an incentive spirometer (IS) improves respiratory symptoms and functional status in Long COVID. In Taiwan, NRICM101 is commonly used during the acute phase; however, its impact on rehabilitation outcomes remains unclear. Objective: This study evaluated the effects of IS-based respiratory training and the potential influence of prior NRICM101 use. Methods: Participants were grouped by time since recovery, and pre-post changes after six weeks of IS training were compared between those with and without self-reported prior NRICM101 use. Primary outcomes were dyspnea and functional status; secondary outcomes included six-minute walk distance and arterial oxygen content. Results: IS training significantly improved dyspnea (p < 0.0001), functional status (p < 0.0001), and exercise endurance (NRICM101 group: p = 0.002; no NRICM101 group: p < 0.0001). Stratified analysis showed that when initiated within three months of recovery, participants without prior NRICM101 use had greater improvements in dyspnea (p < 0.0001), functional status (p = 0.001), and exercise endurance (p < 0.0001). Conclusions: Prior NRICM101 use may be associated with different rehabilitation patterns, likely reflecting differences in recovery trajectory or patient behavior rather than purely pharmacological effects.
- Open Access
- 13 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1620317
Case Report: Percutaneous catheter drainage in the treatment of amebic liver abscess with syphilis infections — a case study and literature review
Introduction: Amebic liver abscesses (ALAs) result from Entamoeba histolytica, a protozoan parasite transmitted through contaminated food or water. Diagnosis relies on imaging and serology, and treatment typically involves antibiotics such as metronidazole.Case presentation: Herein, we present a case of a 47-year-old man who presented with hepatitis B virus and syphilis infections during admission. Laboratory tests and computed tomography scan revealed a liver abscess. Percutaneous catheter drainage (PCD) was conducted on the day of admission. Positive amebiasis titers confirmed ALAs. Although culture of the purulent material from the abscess later showed no bacterial growth, ceftriaxone and metronidazole were kept empirically. The patient was discharged in stable clinical condition, and the drainage tube was removed 2 weeks after discharge.Conclusion: Our case demonstrated a scenario in which continuous PCD was initiated alongside traditional medical treatment in the risk group for ALAs and PCD complications. The symptoms were successfully relieved, and he recovered well without any complications.
- 13 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1620317
Open AccessCase Report: Percutaneous catheter drainage in the treatment of amebic liver abscess with syphilis infections — a case study and literature review
Introduction: Amebic liver abscesses (ALAs) result from Entamoeba histolytica, a protozoan parasite transmitted through contaminated food or water. Diagnosis relies on imaging and serology, and treatment typically involves antibiotics such as metronidazole.Case presentation: Herein, we present a case of a 47-year-old man who presented with hepatitis B virus and syphilis infections during admission. Laboratory tests and computed tomography scan revealed a liver abscess. Percutaneous catheter drainage (PCD) was conducted on the day of admission. Positive amebiasis titers confirmed ALAs. Although culture of the purulent material from the abscess later showed no bacterial growth, ceftriaxone and metronidazole were kept empirically. The patient was discharged in stable clinical condition, and the drainage tube was removed 2 weeks after discharge.Conclusion: Our case demonstrated a scenario in which continuous PCD was initiated alongside traditional medical treatment in the risk group for ALAs and PCD complications. The symptoms were successfully relieved, and he recovered well without any complications.
- Open Access
- 1 June 2025
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 18, 1849-1858
Effectiveness of a Structured 2-Year Diabetes Health Education Program of Patients with Type 2 Diabetes Mellitus in Disease-Related Serum Markers
Introduction: Previous studies on the impact of diabetes education on disease management have shown that different educational approaches yield varying degrees of effectiveness across different populations. Adopting face-to-face education with long-term follow-up not only allows for monitoring changes in numerical values but also facilitates the observation of patients’ learning status. Methods: This study investigates the impact of a two-year structured Diabetes Health Education (DHE) program on disease-related serum markers in patients with type 2 diabetes mellitus (T2DM). A five-year observational cohort study with retrospective analysis was conducted, involving 1,080 participants who completed the DHE program and 192 non-participants. Results: The DHE program included regular educational sessions every three months, covering topics such as blood glucose management, lipid profiles, and healthy lifestyle practices. Results demonstrated significant improvements among DHE participants: HbA1c levels decreased by 37%, fasting glucose by 4%, total cholesterol by 7%, LDL cholesterol by 13%, and triglycerides by 20%, with HDL cholesterol increasing by 3%. Body weight and diastolic blood pressure (DBP) also showed reductions of 4% and 3%, respectively, while systolic blood pressure (SBP) exhibited no significant changes. The improvements in lipid profiles were evident within six months, whereas glycemic markers required at least 1.5 years to achieve significance. Conclusion: These results suggest that a structured DHE program significantly improves glycemic control, lipid profile, and other metabolic-related markers in patients with T2DM. Notably, HbA1c and fasting glucose levels significantly improved after 1.5 years of consistent DHE participation, highlighting the importance of long-term engagement for glycemic benefits.
- 1 June 2025
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 18, 1849-1858
Open AccessEffectiveness of a Structured 2-Year Diabetes Health Education Program of Patients with Type 2 Diabetes Mellitus in Disease-Related Serum Markers
Introduction: Previous studies on the impact of diabetes education on disease management have shown that different educational approaches yield varying degrees of effectiveness across different populations. Adopting face-to-face education with long-term follow-up not only allows for monitoring changes in numerical values but also facilitates the observation of patients’ learning status. Methods: This study investigates the impact of a two-year structured Diabetes Health Education (DHE) program on disease-related serum markers in patients with type 2 diabetes mellitus (T2DM). A five-year observational cohort study with retrospective analysis was conducted, involving 1,080 participants who completed the DHE program and 192 non-participants. Results: The DHE program included regular educational sessions every three months, covering topics such as blood glucose management, lipid profiles, and healthy lifestyle practices. Results demonstrated significant improvements among DHE participants: HbA1c levels decreased by 37%, fasting glucose by 4%, total cholesterol by 7%, LDL cholesterol by 13%, and triglycerides by 20%, with HDL cholesterol increasing by 3%. Body weight and diastolic blood pressure (DBP) also showed reductions of 4% and 3%, respectively, while systolic blood pressure (SBP) exhibited no significant changes. The improvements in lipid profiles were evident within six months, whereas glycemic markers required at least 1.5 years to achieve significance. Conclusion: These results suggest that a structured DHE program significantly improves glycemic control, lipid profile, and other metabolic-related markers in patients with T2DM. Notably, HbA1c and fasting glucose levels significantly improved after 1.5 years of consistent DHE participation, highlighting the importance of long-term engagement for glycemic benefits.
- Open Access
- 1 November 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 5233-5246
A Narrative Review of Impact of Incentive Spirometer Respiratory Training in Long COVID
Long COVID refers to symptoms that appear 3 months after initial infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus of Coronavirus disease 2019 (COVID-19), and last for at least 2 months, not attributable to other diagnoses. This health issue significantly burdens patients’ quality of life, the economy, and society. Improving the af-termath of COVID-19 is a crucial global health issue in the post-pandemic era. According to current results, it is evident that developing a simple, low-cost respiratory training method that can be easily used at home by themselves with long Coronavirus disease 2019 symptoms (long COVID) is an important and urgent issue. The incentive spirometer is widely used in physical, speech, and respiratory therapy, as well as in preventing postoperative pulmonary infections and improving sputum clearance. However, to date, the role of incentive spirometer respiratory training in long COVID symptoms is still limited. In this literature review is presented to explore the effectiveness of incentive spirometer respiratory training in alleviating symptoms among individuals recovering from long COVID. We also compile non-invasive assessment methods, with the aim to enable individuals to undergo training and assessments conveniently at home or in the community. In this review, a literature review approach was utilized to explore the effectiveness of incentive spirometer intervention in alleviating long-term COVID symptoms. This study is to synthesize the findings of articles published during January 2019 and December 2023 retrieved from PubMed/CINAHL/MEDLINE/ Google Scholar without re-strictions on study type. We ultimately identified seven articles and have summarized similar past studies. This review could contribute to improving symptoms related to long COVID by incentive spirometer respiratory training and serve as practical reference material for clinical medical staff and provide insights for healthcare policymakers in de-veloping guidelines for future research directions, clinical guidance, and educational strategies in the context of nursing care.
- 1 November 2024
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 17, 5233-5246
Open AccessA Narrative Review of Impact of Incentive Spirometer Respiratory Training in Long COVID
Long COVID refers to symptoms that appear 3 months after initial infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus of Coronavirus disease 2019 (COVID-19), and last for at least 2 months, not attributable to other diagnoses. This health issue significantly burdens patients’ quality of life, the economy, and society. Improving the af-termath of COVID-19 is a crucial global health issue in the post-pandemic era. According to current results, it is evident that developing a simple, low-cost respiratory training method that can be easily used at home by themselves with long Coronavirus disease 2019 symptoms (long COVID) is an important and urgent issue. The incentive spirometer is widely used in physical, speech, and respiratory therapy, as well as in preventing postoperative pulmonary infections and improving sputum clearance. However, to date, the role of incentive spirometer respiratory training in long COVID symptoms is still limited. In this literature review is presented to explore the effectiveness of incentive spirometer respiratory training in alleviating symptoms among individuals recovering from long COVID. We also compile non-invasive assessment methods, with the aim to enable individuals to undergo training and assessments conveniently at home or in the community. In this review, a literature review approach was utilized to explore the effectiveness of incentive spirometer intervention in alleviating long-term COVID symptoms. This study is to synthesize the findings of articles published during January 2019 and December 2023 retrieved from PubMed/CINAHL/MEDLINE/ Google Scholar without re-strictions on study type. We ultimately identified seven articles and have summarized similar past studies. This review could contribute to improving symptoms related to long COVID by incentive spirometer respiratory training and serve as practical reference material for clinical medical staff and provide insights for healthcare policymakers in de-veloping guidelines for future research directions, clinical guidance, and educational strategies in the context of nursing care.
- 24 September 2024
- Published by Springer Nature in Sports Medicine
- Vol. 54 (12) , 3215-3216
Comment on: “Premature Death in Bodybuilders: What Do We Know?”
- 24 September 2024
- Published by Springer Nature in Sports Medicine
- Vol. 54 (12) , 3215-3216
Comment on: “Premature Death in Bodybuilders: What Do We Know?”
- Open Access
Association between Thyroid Profile Levels and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Retrospective Study
Background: Thyroid cancer is the most common endocrine carcinoma, accounting for 3.26% of all cancers. The most histologically, well-differentiated thyroid cancer is papillary thyroid carcinoma (PTC). Although PTC is regarded as an indolent tumor, a portion of the cancer cells metastasize to lymph nodes around the thyroid gland. Lymph node metastasis (LNM) is a critical risk factor for tumor recurrence in PTC, which strongly affects disease prognosis and the quality of life. Methods: This study aims to examine how differences in the level of the thyroid profile and other risk factors may influence LNM incidence in patients with PTC in Taiwan. We carried out a single-center retrospective study. These PTC patients were retrospectively reviewed by the Department of Endocrinology from 2016 to 2019. A total of 165 patients were included in our research. Results: The findings revealed a close relationship with the level of free thyroxine (FT4), the level of the thyroid-stimulating hormone (TSH), and lymph node metastases. The correlation in terms of FT4 (p = 0.005) and TSH (p = 0.417) with LNM was found as a result of the univariate regression analysis. In the multiple regression analysis, the findings revealed a close relationship between LNM, FT4 (p < 0.001), and TSH (p = 0.008). Conclusions: Although the predictability of the TSH should be examined further, the association between LNM and FT4 or TSH should not be ignored. The results could help guide decision-making and patient counseling, using the level of serum FT4 or the TSH as a possible predictive factor of the LNM in PTC.
Open AccessAssociation between Thyroid Profile Levels and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Retrospective Study
Background: Thyroid cancer is the most common endocrine carcinoma, accounting for 3.26% of all cancers. The most histologically, well-differentiated thyroid cancer is papillary thyroid carcinoma (PTC). Although PTC is regarded as an indolent tumor, a portion of the cancer cells metastasize to lymph nodes around the thyroid gland. Lymph node metastasis (LNM) is a critical risk factor for tumor recurrence in PTC, which strongly affects disease prognosis and the quality of life. Methods: This study aims to examine how differences in the level of the thyroid profile and other risk factors may influence LNM incidence in patients with PTC in Taiwan. We carried out a single-center retrospective study. These PTC patients were retrospectively reviewed by the Department of Endocrinology from 2016 to 2019. A total of 165 patients were included in our research. Results: The findings revealed a close relationship with the level of free thyroxine (FT4), the level of the thyroid-stimulating hormone (TSH), and lymph node metastases. The correlation in terms of FT4 (p = 0.005) and TSH (p = 0.417) with LNM was found as a result of the univariate regression analysis. In the multiple regression analysis, the findings revealed a close relationship between LNM, FT4 (p < 0.001), and TSH (p = 0.008). Conclusions: Although the predictability of the TSH should be examined further, the association between LNM and FT4 or TSH should not be ignored. The results could help guide decision-making and patient counseling, using the level of serum FT4 or the TSH as a possible predictive factor of the LNM in PTC.
- Open Access
Unusual body weight loss due to primary hyperparathyroidism: A case study with literature review
- Open Access
- 20 September 2023
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 23 (1) , 1-6
Newly diagnosed type 1 diabetes mellitus in a human immunodeficiency virus-infected patient with antiretroviral therapy-induced immune reconstitution inflammatory syndrome: a case report
Diabetes that develops in human immunodeficiency virus (HIV)-infected patients who receive antiretroviral therapy (ART) is usually type 2 diabetes mellitus (T2DM); however, autoimmune diabetes, such as type 1 diabetes mellitus (T1DM) can also develop in this population. After treatment with ART, patients might experience clinical deterioration following an increase in the CD4 cell count, which is termed immune reconstitution inflammatory syndrome (IRIS). Here, we describe an HIV-infected patient on ART who developed T1DMat due to IRIS, highlighting the clinical complexity in diagnosis and treatment. A 36-year-old man infected with HIV had a nadir CD4 cell count of 15.53/μL before medication, which increased to 429.09/μL after 9 months of regular ART. The fasting serum glucose at 9 months was between 96 mg/dL and 117 mg/dL. After 11 months of ART, the patient was admitted to hospital for diabetic ketoacidosis (DKA) and Graves’ disease (GD). Noninsulin antidiabetics (NIADs) were prescribed following the resolution of DKA. However, poor glycemic control was noted despite well-titrated NIADs. Further investigation demonstrated poor pancreatic beta cell function and elevated anti-glutamic acid decarboxylase (anti-GAD) and anti-tyrosine phosphatase-like insulinoma antigen 2 (anti-IA2) titers. According to the results, he was diagnosed with T1DM and received multiple daily injections(MDI) of insulin. The regimen of MDI was insulin degludec as basal insulin and insulin aspart as prandial insulin. After MDI therapy, his glycemic control was improved. In this case, T1DM was ascribed to IRIS. Although this phenomenon has been demonstrated in previous case reports, further study is necessary to realize the mechanism of this association. Therefore, we emphasize that when HIV-infected patients on ART experience an unstable blood glucose level and abnormal thyroid function, physicians should consider T1DM and GD associated with ART-induced IRIS to reduce the subsequent complications and more serious endocrine dysfunction.
- 20 September 2023
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 23 (1) , 1-6
Open AccessNewly diagnosed type 1 diabetes mellitus in a human immunodeficiency virus-infected patient with antiretroviral therapy-induced immune reconstitution inflammatory syndrome: a case report
Diabetes that develops in human immunodeficiency virus (HIV)-infected patients who receive antiretroviral therapy (ART) is usually type 2 diabetes mellitus (T2DM); however, autoimmune diabetes, such as type 1 diabetes mellitus (T1DM) can also develop in this population. After treatment with ART, patients might experience clinical deterioration following an increase in the CD4 cell count, which is termed immune reconstitution inflammatory syndrome (IRIS). Here, we describe an HIV-infected patient on ART who developed T1DMat due to IRIS, highlighting the clinical complexity in diagnosis and treatment. A 36-year-old man infected with HIV had a nadir CD4 cell count of 15.53/μL before medication, which increased to 429.09/μL after 9 months of regular ART. The fasting serum glucose at 9 months was between 96 mg/dL and 117 mg/dL. After 11 months of ART, the patient was admitted to hospital for diabetic ketoacidosis (DKA) and Graves’ disease (GD). Noninsulin antidiabetics (NIADs) were prescribed following the resolution of DKA. However, poor glycemic control was noted despite well-titrated NIADs. Further investigation demonstrated poor pancreatic beta cell function and elevated anti-glutamic acid decarboxylase (anti-GAD) and anti-tyrosine phosphatase-like insulinoma antigen 2 (anti-IA2) titers. According to the results, he was diagnosed with T1DM and received multiple daily injections(MDI) of insulin. The regimen of MDI was insulin degludec as basal insulin and insulin aspart as prandial insulin. After MDI therapy, his glycemic control was improved. In this case, T1DM was ascribed to IRIS. Although this phenomenon has been demonstrated in previous case reports, further study is necessary to realize the mechanism of this association. Therefore, we emphasize that when HIV-infected patients on ART experience an unstable blood glucose level and abnormal thyroid function, physicians should consider T1DM and GD associated with ART-induced IRIS to reduce the subsequent complications and more serious endocrine dysfunction.